SLU-PP-332 50mg

Description

SLU-PP-332 50mg is at the frontier of documented research dosing — a level that comprehensively saturates ERR receptor engagement and drives the full breadth of the compound’s transcriptional programme across metabolic tissues. At this dose, the gene expression shift in skeletal muscle approaches the phenotypic endpoint observed in chronically endurance-adapted athletes — with the entire mitochondrial biogenesis, fatty acid oxidation, and slow-twitch fibre transition cascade fully engaged. The systemic metabolic improvements compound with dose: fat mass reduction, insulin sensitivity enhancement, cardiovascular efficiency gains, and lean tissue preservation are all maximal at this level. This is a research dose for advanced protocols with appropriate monitoring infrastructure. The compound’s novelty means long-term human pharmacodynamics at this level are still being characterised. What can be guaranteed is purity and dose accuracy — independently verified at 99%+ by Puralytix. At 50mg, compound interactions with other medications and supplements should be evaluated with particular care. Systematic medical monitoring and detailed symptom tracking are advisable infrastructure for research at this dose level.